ClinicalTrials.gg
CompletedNCT03078556Updated Feb 21, 2019Results posted

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

A Phase 1 interventional study of Dolutegravir and Lamivudine in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-21.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study aims to compare the bioequivalence of two experimental fixed dose combination (FDC) tablets versus single entity products of dolutegravir (DTG) and lamivudine (3TC) in healthy adult subjects. The study will be carried out in two parts. Part 1 of the study will be open label, up to 3 periods design with a wash out period of at least 7 days between treatment periods. Subjects will be randomized to receive either single entities or formulation 1 FDC of DTG and 3TC in a crossover manner in first 2 periods. The first 16 subjects who complete the first two treatment periods and consent to continue will receive a single dose of FDC formulation 1 tablet administered with a high fat meal for a third treatment period. In Part 2 of the study, subjects will be randomized to receive either single entities or formulation 2 FDC of DTG and 3TC in a crossover manner in first 2 periods. Similarly the first 16 subjects will then receive FDC formulation 2 tablets with high fat meal in treatment period 3. Subjects will have a follow-up visit within 7-14 days after the last dose of study drug. Approximately 76 healthy subjects will be included in Part 1 of the study and if Part 2 of the study is conducted, another 76 healthy subjects will be included. The total duration will be approximately 11 weeks.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • FDC
  • Lamivudine
  • Bio-equivalence
  • Dolutegravir
  • HIV
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 154 is above the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 55 years of age inclusive, at the time of signing the .
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac evaluation (history, [ECG]).
  • A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator, in consultation with the Medical Monitor if required, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Subject must be able to swallow 2 tablets at the same time (Reference tablets only).
  • Body weight >=50 kilogram (kg) for men and >=45 kg for women and (BMI) within the range 18.5-31.0 kg per meter square (kg/m\^2).
  • Male or Female. Female subject: is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: 1. non- defined as: pre-menopausal females with one of the following: documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; documented bilateral Oophorectomy. defined as 12 months of spontaneous amenorrhea; in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. 2. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication and until at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer after the last dose of study medication and completion of the follow-up visit.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions.

Exclusion criteria

Exclusion Criteria:

  • (ALT) and >1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percentage).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • corrected for heart rate according to Fridericia's formula (QTcF) > 450 milliseconds (msec).
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and ViiV Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces [360 milliliter (mL)] of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 1 month prior to screening.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • (CrCL) \<90 mL/minute.
  • A positive surface antigen (HBsAg) or a positive hepatitis B core antibody with a negative hepatitis B surface antibody, positive antibody test result at screening or within 3 months prior to first dose of study treatment.
  • A positive pre-study drug/alcohol screen.
  • A positive test for antibody.
  • Where participation in the study would result in donation of blood or blood product in excess of 500 mL within 56 days.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Treatment sequence A/B: Part 1

    Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.

    Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 1

  • Experimental
    Treatment sequence B/A: Part 1

    Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.

    Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 1

  • Experimental
    Subjects receiving high fat meal: Part 1

    Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.

    Drug: Dolutegravir + Lamivudine FDC Formulation 1

  • Experimental
    Treatment sequence A/C: Part 2

    Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.

    Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 2

  • Experimental
    Treatment sequence C/A: Part 2

    Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.

    Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 2

  • Experimental
    Subjects receiving high fat meal: Part 2

    Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.

    Drug: Dolutegravir + Lamivudine FDC Formulation 2

Interventions

  • Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.

  • Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br\>3TC will be gray, diamond shaped tablet, engraved "GX EJ7" on one side and plain on the other side.

  • DrugDolutegravir + Lamivudine FDC Formulation 1

    Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.

  • DrugDolutegravir + Lamivudine FDC Formulation 2

    Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity [AUC (0-Inf)] of Plasma DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the pharmacokinetic (PK) profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  2. AUC (0-Inf) of Plasma DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at given time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted conditions in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  3. Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Time Point (AUC[0-t]) of Plasma DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  4. AUC(0-t) of Plasma DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  5. Maximum Observed Concentration (Cmax) of Plasma DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  6. Cmax of Plasma DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

Secondary outcomes

  1. Absorption Lag Time (Tlag) of DTG and 3TC in Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  2. Tlag of DTG and 3TC in Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  3. Time to Reach Maximum Plasma Concentration (Tmax) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  4. Tmax of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  5. Time of the Last Quantifiable Concentration (Tlast) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  6. Tlast of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  7. Time to Reach Half the Maximum Plasma Concentration (t1/2) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  8. t1/2 of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  9. Apparent Elimination Rate Constant (Lambda z) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  10. Lambda z of DTG and 3TC in in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  11. Percentage of Extrapolated AUC (0 to Inf) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  12. Percentage of Extrapolated AUC(0 to Inf) of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  13. AUC of 0 to 24 Hours (AUC[0-24]) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  14. AUC(0-24) of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  15. Apparent Oral Clearance (CL/F) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  16. CL/F of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  17. Apparent Oral Volume of Distribution (Vz/F) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  18. Vz/F of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  19. Concentration at 24 Hours Post-dose (C24) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  20. C24 of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  21. Last Quantifiable Concentration (Clast) of DTG and 3TC in the Fasted State: Part 1

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  22. Clast of DTG and 3TC in the Fasted State: Part 2

    Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  23. AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  24. AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  25. AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  26. AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  27. Cmax of Plasma DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  28. Cmax of Plasma DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  29. Tlag of DTG and 3TC in Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  30. Tlag of DTG and 3TC in Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  31. Tmax of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  32. Tmax of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  33. T1/2 of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  34. T1/2 of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  35. Lambda z of DTG and 3TC in in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  36. Lambda z of DTG and 3TC in in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  37. Clast of DTG and 3TC in in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  38. Clast of DTG and 3TC in in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  39. Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  40. Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  41. AUC(0-24) of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  42. AUC(0-24) of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  43. CL/F of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  44. CL/F of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  45. Tlast of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  46. Tlast of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  47. Vz/F of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  48. Vz/F of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  49. C24 of DTG and 3TC in the Fed State: Part 1

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  50. C24 of DTG and 3TC in the Fed State: Part 2

    Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  51. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Part 1 and 2

    SBP and DBP were measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for SBP and DBP for Part 1 and 2 is presented.

    Time frame: Up to Day 31 in Part 1 and Part 2

  52. Change From Baseline in Heart Rate (HR): Part 1 and 2

    HR was measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for HR for Part 1 and 2 is presented.

    Time frame: Up to Day 31 in Part 1 and Part 2

  53. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 and 2

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia were categorized as SAE. Participants having any AE or SAE are presented.

    Time frame: Up to Week 11

07

Results

Posted Feb 21, 2019

Participant flow

The study was conducted in 2 parts (Part 1 and Part 2) at a single center in the United States from 27-March-2017 to 18-August-2017 and 154 participants (78 in Part 1 and 76 in Part 2) were randomized. First 16 participants completing the first 2 dosing periods, returned for a 3rd treatment period and received single dose of FDC with high fat meal

Treatment Period 1 (4 Days)
Participant flow — Treatment Period 1 (4 Days)
MilestonePart 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fedPart 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fedPart 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fedPart 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed
Started39393838
Completed39383838
Not completed0100
Withdrew: Adverse event0100
Washout Period 1 (7 Days)
Participant flow — Washout Period 1 (7 Days)
MilestonePart 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fedPart 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fedPart 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fedPart 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed
Started39383838
Completed37363737
Not completed2211
Withdrew: Lost to follow-up2010
Withdrew: Adverse event0101
Withdrew: Physician decision0100
Treatment Period 2 (4 Days)
Participant flow — Treatment Period 2 (4 Days)
MilestonePart 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fedPart 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fedPart 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fedPart 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed
Started37363737
Completed37363737
Not completed0000
Washout Period 2 (7 Days)
Participant flow — Washout Period 2 (7 Days)
MilestonePart 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fedPart 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fedPart 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fedPart 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed
Started9779
Completed9779
Not completed0000
Treatment Period 3 (4 Days)
Participant flow — Treatment Period 3 (4 Days)
MilestonePart 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fedPart 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fedPart 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fedPart 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed
Started9779
Completed9779
Not completed0000

Outcome measures

PrimaryArea Under the Concentration-time Curve From Time 0 Extrapolated to Infinity [AUC (0-Inf)] of Plasma DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the pharmacokinetic (PK) profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hour*micrograms per milliliter
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity [AUC (0-Inf)] of Plasma DTG and 3TC in the Fasted State: Part 1
Hour*micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG43.1456 ± 39.2954.8793 ± 31.60
3TC12.3337 ± 19.8812.7603 ± 19.77
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.2710 · 90% CI 1.1894 to 1.3582Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.0341 · 90% CI 1.0097 to 1.0591Ratio (B/A) of plasma 3TC has been presented.
PrimaryAUC (0-Inf) of Plasma DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at given time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted conditions in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*micrograms per milliliter
AUC (0-Inf) of Plasma DTG and 3TC in the Fasted State: Part 2
Hours*micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG, n= 74,7447.2391 ± 40.2954.5594 ± 32.12
3TC, n= 73,7412.7713 ± 18.6313.5624 ± 17.94
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.1550 · 90% CI 1.0699 to 1.2468Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.0635 · 90% CI 1.0413 to 1.0861Ratio (C/A) of plasma 3TC has been presented.
PrimaryArea Under the Concentration-time Curve From Time 0 to the Last Quantifiable Time Point (AUC[0-t]) of Plasma DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*micrograms per milliliter
Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Time Point (AUC[0-t]) of Plasma DTG and 3TC in the Fasted State: Part 1
Hours*micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG41.4207 ± 39.3652.8754 ± 31.16
3TC12.1571 ± 20.1912.6147 ± 19.75
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.2756 · 90% CI 1.1919 to 1.3651Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.0372 · 90% CI 1.0116 to 1.0634Ratio (B/A) of plasma 3TC has been presented.
PrimaryAUC(0-t) of Plasma DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hour*microgram/milliliter
AUC(0-t) of Plasma DTG and 3TC in the Fasted State: Part 2
Hour*microgram/milliliterA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG45.2043 ± 39.5752.3372 ± 31.46
3TC12.4790 ± 19.1913.3552 ± 18.10
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.1578 · 90% CI 1.0718 to 1.2507Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.0702 · 90% CI 1.0464 to 1.0946Ratio (C/A) of plasma 3TC has been presented.
PrimaryMaximum Observed Concentration (Cmax) of Plasma DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Observed Concentration (Cmax) of Plasma DTG and 3TC in the Fasted State: Part 1
Micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG2.4065 ± 38.953.0817 ± 31.86
3TC2.6650 ± 29.043.1885 ± 28.07
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.2805 · 90% CI 1.1890 to 1.3790Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.1956 · 90% CI 1.1437 to 1.2498Ratio (B/A) of plasma 3TC has been presented.
PrimaryCmax of Plasma DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Plasma DTG and 3TC in the Fasted State: Part 2
Micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG2.5531 ± 36.382.9132 ± 30.55
3TC2.4428 ± 28.253.2185 ± 29.30
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.1410 · 90% CI 1.0533 to 1.2361Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.3176 · 90% CI 1.2616 to 1.3760Ratio (C/A) of plasma 3TC has been presented.
SecondaryAbsorption Lag Time (Tlag) of DTG and 3TC in Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Absorption Lag Time (Tlag) of DTG and 3TC in Fasted State: Part 1
HourA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG0.0000 (0.0000 to 0.756)0.0000 (0.0000 to 0.261)
3TC0.0000 (0.0000 to 0.252)0.0000 (0.0000 to 0.261)
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Median difference (final values): 0.000 · 90% CI 0.000 to 0.000Median Difference of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Median difference (final values): 0.000 · 90% CI 0.000 to 0.000Median Difference of plasma 3TC has been presented.
SecondaryTlag of DTG and 3TC in Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tlag of DTG and 3TC in Fasted State: Part 2
HourA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG0.0000 (0.0000 to 0.261)0.0000 (0.0000 to 0.266)
3TC0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.252)
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Median difference (final values): 0.000 · 90% CI -0.004 to 0.000Median Difference of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Median difference (final values): 0.000 · 90% CI 0.000 to 0.000Median Difference of plasma 3TC has been presented.
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Time to Reach Maximum Plasma Concentration (Tmax) of DTG and 3TC in the Fasted State: Part 1
HourA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG2.0072 (0.500 to 8.009)2.0017 (0.500 to 5.012)
3TC1.0047 (0.500 to 4.005)1.0008 (0.500 to 3.500)
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Median difference (final values): -0.127 · 90% CI -0.500 to 0.248Median Difference of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Median difference (final values): -0.126 · 90% CI -0.253 to -0.001Median Difference of plasma 3TC has been presented.
SecondaryTmax of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tmax of DTG and 3TC in the Fasted State: Part 2
HourA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG2.5008 (0.500 to 5.011)2.5004 (0.500 to 6.001)
3TC1.0063 (0.500 to 4.002)1.0011 (0.500 to 3.501)
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Median difference (final values): -0.127 · 90% CI -0.497 to 0.132Median Difference of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Median difference (final values): -0.248 · 90% CI -0.376 to -0.001Median Difference of plasma 3TC has been presented.
SecondaryTime of the Last Quantifiable Concentration (Tlast) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Time of the Last Quantifiable Concentration (Tlast) of DTG and 3TC in the Fasted State: Part 1
HourA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG72.0031 (48.000 to 74.636)71.9303 (48.003 to 76.236)
3TC71.9289 (47.673 to 74.636)71.9303 (70.790 to 76.236)
SecondaryTlast of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tlast of DTG and 3TC in the Fasted State: Part 2
HourA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG71.6813 (48.006 to 75.301)71.8243 (71.005 to 72.632)
3TC71.7138 (48.000 to 75.301)71.8153 (48.007 to 72.632)
SecondaryTime to Reach Half the Maximum Plasma Concentration (t1/2) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Time to Reach Half the Maximum Plasma Concentration (t1/2) of DTG and 3TC in the Fasted State: Part 1
HourA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG14.6917 (10.575 to 21.375)14.7557 (10.461 to 21.392)
3TC17.0395 (8.281 to 34.542)17.3436 (12.436 to 34.675)
Secondaryt1/2 of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
t1/2 of DTG and 3TC in the Fasted State: Part 2
HourA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG, n= 74,7415.1538 (9.711 to 21.966)14.7893 (9.815 to 21.486)
3TC, n= 73,7417.8421 (10.195 to 47.171)18.1071 (7.367 to 48.613)
SecondaryApparent Elimination Rate Constant (Lambda z) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Per hour
Apparent Elimination Rate Constant (Lambda z) of DTG and 3TC in the Fasted State: Part 1
Per hourA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG0.0472 (0.032 to 0.066)0.0470 (0.032 to 0.066)
3TC0.0407 (0.020 to 0.084)0.0400 (0.020 to 0.056)
SecondaryLambda z of DTG and 3TC in in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Per hour
Lambda z of DTG and 3TC in in the Fasted State: Part 2
Per hourA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG, n=74,740.0457 (0.032 to 0.071)0.0469 (0.032 to 0.071)
3TC, n= 73,740.0388 (0.015 to 0.068)0.0383 (0.014 to 0.094)
SecondaryPercentage of Extrapolated AUC (0 to Inf) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Percentage of AUC
Percentage of Extrapolated AUC (0 to Inf) of DTG and 3TC in the Fasted State: Part 1
Percentage of AUCA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG3.4967 (1.015 to 15.084)3.2582 (0.908 to 9.967)
3TC1.0287 (0.343 to 7.305)0.9052 (0.428 to 5.334)
SecondaryPercentage of Extrapolated AUC(0 to Inf) of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Percentage of AUC
Percentage of Extrapolated AUC(0 to Inf) of DTG and 3TC in the Fasted State: Part 2
Percentage of AUCA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG, n= 74,743.8923 (0.932 to 10.512)3.5773 (0.659 to 9.570)
3TC, n= 73,741.2518 (0.344 to 6.409)1.1432 (0.394 to 7.867)
SecondaryAUC of 0 to 24 Hours (AUC[0-24]) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC of 0 to 24 Hours (AUC[0-24]) of DTG and 3TC in the Fasted State: Part 1
Hours*microgram per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG29.4257 ± 38.4037.6112 ± 30.28
3TC11.3960 ± 20.9211.9418 ± 20.09
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.2774 · 90% CI 1.1931 to 1.3676Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.0475 · 90% CI 1.0185 to 1.0773Ratio (B/A) of plasma 3TC has been presented.
SecondaryAUC(0-24) of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-24) of DTG and 3TC in the Fasted State: Part 2
Hours*microgram per milliliterA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG31.5664 ± 37.7336.6126 ± 30.93
3TC11.6419 ± 20.2312.5810 ± 18.50
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.1599 · 90% CI 1.0711 to 1.2560Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.0807 · 90% CI 1.0539 to 1.1081Ratio (C/A) of plasma 3TC has been presented.
SecondaryApparent Oral Clearance (CL/F) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters per hour
Apparent Oral Clearance (CL/F) of DTG and 3TC in the Fasted State: Part 1
Liters per hourA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG1.1589 ± 39.290.9111 ± 31.60
3TC24.3236 ± 19.8823.5104 ± 19.77
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 0.7868 · 90% CI 0.7363 to 0.8408Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 0.9670 · 90% CI 0.9442 to 0.9904Ratio (B/A) of plasma 3TC has been presented.
SecondaryCL/F of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters per hour
CL/F of DTG and 3TC in the Fasted State: Part 2
Liters per hourA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG, n= 74, 741.0584 ± 40.290.9164 ± 32.12
3TC, n= 73, 7423.4901 ± 18.6322.1200 ± 17.94
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 0.8658 · 90% CI 0.8021 to 0.9347Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 0.9403 · 90% CI 0.9207 to 0.9604Ratio (C/A) of plasma 3TC has been presented.
SecondaryApparent Oral Volume of Distribution (Vz/F) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Oral Volume of Distribution (Vz/F) of DTG and 3TC in the Fasted State: Part 1
LitersA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG24.6254 ± 37.8019.3399 ± 30.05
3TC616.7365 ± 34.52598.8651 ± 29.07
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 0.7859 · 90% CI 0.7318 to 0.8440Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 0.9704 · 90% CI 0.9157 to 1.0284Ratio (B/A) of plasma 3TC has been presented.
SecondaryVz/F of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters
Vz/F of DTG and 3TC in the Fasted State: Part 2
LitersA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG, n= 74, 7423.1159 ± 37.1819.8124 ± 32.73
3TC, n= 73, 74650.7952 ± 35.55599.5525 ± 34.28
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 0.8571 · 90% CI 0.7914 to 0.9282Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 0.9153 · 90% CI 0.8613 to 0.9728Ratio (C/A) of plasma 3TC has been presented.
SecondaryConcentration at 24 Hours Post-dose (C24) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Concentration at 24 Hours Post-dose (C24) of DTG and 3TC in the Fasted State: Part 1
Micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG0.6373 ± 40.180.8059 ± 32.77
3TC0.0331 ± 32.130.0318 ± 31.81
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.2632 · 90% CI 1.1811 to 1.3511Ratio (B/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 0.9598 · 90% CI 0.9268 to 0.9941Ratio (B/A) of plasma 3TC has been presented.
SecondaryC24 of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
C24 of DTG and 3TC in the Fasted State: Part 2
Micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG0.7065 ± 41.480.8071 ± 33.83
3TC0.0366 ± 30.390.0350 ± 31.19
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.1425 · 90% CI 1.0597 to 1.2317Ratio (C/A) of plasma DTG has been presented.
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 0.9548 · 90% CI 0.9299 to 0.9804Ratio (C/A) of plasma 3TC has been presented.
SecondaryLast Quantifiable Concentration (Clast) of DTG and 3TC in the Fasted State: Part 1

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Last Quantifiable Concentration (Clast) of DTG and 3TC in the Fasted State: Part 1
Micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgB: DTG 50 mg/ 3TC 300 mg Monolayer FDC
DTG0.0702 ± 58.850.0832 ± 56.42
3TC0.0056 ± 43.030.0050 ± 37.58
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 1.1839 · 90% CI 1.0921 to 1.2834Ratio (B/A) of plasma DTG has been presented
  • A: DTG 50 mg + EPIVIR 300 mg vs B: DTG 50 mg/ 3TC 300 mg Monolayer FDC · Ratio: 0.8874 · 90% CI 0.8340 to 0.9443Ratio (B/A) of plasma 3TC has been presented
SecondaryClast of DTG and 3TC in the Fasted State: Part 2

Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Clast of DTG and 3TC in the Fasted State: Part 2
Micrograms per milliliterA: DTG 50 mg + EPIVIR 300 mgC: DTG 50 mg/ 3TC 300 mg Bilayer FDC
DTG0.0800 ± 66.940.0862 ± 65.26
3TC0.0069 ± 47.830.0062 ± 41.60
Statistical analysis
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 1.0780 · 90% CI 0.9958 to 1.1670Ratio (B/A) of plasma DTG has been presented
  • A: DTG 50 mg + EPIVIR 300 mg vs C: DTG 50 mg/ 3TC 300 mg Bilayer FDC · Ratio: 0.9049 · 90% CI 0.8474 to 0.9663Ratio (B/A) of plasma 3TC has been presented
SecondaryAUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 1
Hours*microgram per milliliterB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg/3TC 300 mg Monolayer FDC Fed
DTG62.3435 ± 32.3471.9777 ± 19.99
3TC13.4357 ± 21.0212.8668 ± 18.50
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg/3TC 300 mg Monolayer FDC Fed · Ratio: 1.1545 · 90% CI 1.0208 to 1.3058Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg/3TC 300 mg Monolayer FDC Fed · Ratio: 0.9577 · 90% CI 0.9126 to 1.0049Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryAUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 2
Hours*microgram per milliliterC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG57.6561 ± 35.9376.4283 ± 22.36
3TC14.6420 ± 18.5013.3443 ± 20.34
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.3256 · 90% CI 1.1837 to 1.4845Ratio (Cfed/C) of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 0.9114 · 90% CI 0.8658 to 0.9593Ratio (Cfed/C) of plasma 3TC has been presented
SecondaryAUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hour*microgram per milliliter
AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 1
Hour*microgram per milliliterB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG60.3212 ± 31.7869.2560 ± 18.92
3TC13.2818 ± 20.9012.6491 ± 18.63
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.1481 · 90% CI 1.0154 to 1.2982Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 0.9524 · 90% CI 0.9086 to 0.9983Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryAUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hour*microgram per milliliter
AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 2
Hour*microgram per milliliterC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG55.2176 ± 35.3372.7545 ± 20.22
3TC14.4706 ± 18.7213.0923 ± 20.57
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.3176 · 90% CI 1.1750 to 1.4775Ratio (Cfed/C) of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 0.9048 · 90% CI 0.8592 to 0.9528Ratio (Cfed/C) of plasma 3TC has been presented
SecondaryCmax of Plasma DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Plasma DTG and 3TC in the Fed State: Part 1
Micrograms per milliliterB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG3.5068 ± 30.273.7900 ± 20.97
3TC3.5413 ± 27.142.5132 ± 18.74
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.0808 · 90% CI 0.9527 to 1.2261Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 0.7097 · 90% CI 0.6474 to 0.7779Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryCmax of Plasma DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Plasma DTG and 3TC in the Fed State: Part 2
Micrograms per milliliterC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG3.1015 ± 35.623.7516 ± 21.31
3TC3.5824 ± 35.182.4453 ± 33.88
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.2096 · 90% CI 1.0521 to 1.3908Ratio (Cfed/C) of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 0.6826 · 90% CI 0.5861 to 0.7950Ratio (Cfed/C) of plasma 3TC has been presented
SecondaryTlag of DTG and 3TC in Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tlag of DTG and 3TC in Fed State: Part 1
HourB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG0.0000 (0.0000 to 0.251)0.2522 (0.0000 to 1.000)
3TC0.0000 (0.0000 to 0.251)0.0000 (0.0000 to 0.255)
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Median difference (final values): 0.254 · 90% CI 0.250 to 0.378Median Difference of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Median difference (final values): 0.125 · 90% CI 0.000 to 0.127Median Difference of plasma 3TC has been presented
SecondaryTlag of DTG and 3TC in Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tlag of DTG and 3TC in Fed State: Part 2
HourC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG0.0000 (0.0000 to 0.258)0.1253 (0.0000 to 0.751)
3TC0.0000 (0.0000 to 0.252)0.0000 (0.0000 to 0.257)
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Median difference (final values): 0.126 · 90% CI 0.000 to 0.250Median Difference of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Median difference (final values): 0.000 · 90% CI 0.000 to 0.125Median Difference of plasma 3TC has been presented
SecondaryTmax of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tmax of DTG and 3TC in the Fed State: Part 1
HourB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG1.5013 (0.503 to 5.002)5.0006 (2.001 to 12.009)
3TC1.0001 (0.500 to 2.001)3.5003 (1.011 to 5.006)
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Median difference (final values): 3.017 · 90% CI 1.872 to 4.496Median Difference of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Median difference (final values): 2.113 · 90% CI 1.500 to 2.751Median Difference of plasma 3TC has been presented
SecondaryTmax of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
Tmax of DTG and 3TC in the Fed State: Part 2
HourC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG1.5007 (0.751 to 3.001)5.0019 (1.011 to 8.004)
3TC1.0003 (0.503 to 2.506)2.7508 (1.001 to 6.001)
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Median difference (final values): 2.500 · 90% CI 1.748 to 3.751Median Difference of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Median difference (final values): 1.503 · 90% CI 0.998 to 2.252Median Difference of plasma 3TC has been presented
SecondaryT1/2 of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
T1/2 of DTG and 3TC in the Fed State: Part 1
HourB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG14.5843 (12.077 to 16.806)14.5816 (10.889 to 17.259)
3TC18.3614 (12.509 to 30.759)19.8579 (9.977 to 34.144)
SecondaryT1/2 of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hour
T1/2 of DTG and 3TC in the Fed State: Part 2
HourC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG14.9828 (11.355 to 20.563)15.1718 (12.193 to 19.945)
3TC17.2250 (13.259 to 37.099)19.7311 (13.384 to 27.781)
SecondaryLambda z of DTG and 3TC in in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Per hour
Lambda z of DTG and 3TC in in the Fed State: Part 1
Per hourB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG0.0475 (0.041 to 0.057)0.0475 (0.040 to 0.064)
3TC0.0378 (0.023 to 0.055)0.0349 (0.020 to 0.069)
SecondaryLambda z of DTG and 3TC in in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Per hour
Lambda z of DTG and 3TC in in the Fed State: Part 2
Per hourC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG0.0463 (0.034 to 0.061)0.0457 (0.035 to 0.057)
3TC0.0403 (0.019 to 0.052)0.0351 (0.025 to 0.052)
SecondaryClast of DTG and 3TC in in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Micrograms per milliliter
Clast of DTG and 3TC in in the Fed State: Part 1
Micrograms per milliliterB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG0.1060 (0.035 to 0.180)0.1190 (0.043 to 0.243)
3TC0.0048 (0.003 to 0.014)0.0066 (0.004 to 0.016)
SecondaryClast of DTG and 3TC in in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Micrograms per milliliter
Clast of DTG and 3TC in in the Fed State: Part 2
Micrograms per milliliterC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG0.0975 (0.031 to 0.240)0.1310 (0.051 to 0.363)
3TC0.0059 (0.003 to 0.011)0.0091 (0.003 to 0.015)
SecondaryPercentage of Extrapolated AUC (0-inf) in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Percentage of AUC
Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 1
Percentage of AUCB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG3.3305 (1.490 to 4.845)3.8870 (1.094 to 6.134)
3TC0.8856 (0.561 to 3.510)1.4830 (0.788 to 4.324)
SecondaryPercentage of Extrapolated AUC (0-inf) in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Percentage of AUC
Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 2
Percentage of AUCC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG3.6835 (1.069 to 8.601)3.8790 (1.561 to 9.126)
3TC1.0443 (0.467 to 3.859)1.7467 (0.567 to 3.642)
SecondaryAUC(0-24) of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hour*microgram per milliliter
AUC(0-24) of DTG and 3TC in the Fed State: Part 1
Hour*microgram per milliliterB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG43.1879 ± 29.8846.8555 ± 16.95
3TC12.6113 ± 21.2511.8076 ± 18.71
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.0849 · 90% CI 0.9613 to 1.2245Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 0.9363 · 90% CI 0.8913 to 0.9836Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryAUC(0-24) of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hour*microgram per milliliter
AUC(0-24) of DTG and 3TC in the Fed State: Part 2
Hour*microgram per milliliterC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG38.6325 ± 34.5348.2012 ± 15.53
3TC13.7012 ± 19.2412.1065 ± 21.09
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Median difference (final values): 1.2477 · 90% CI 1.1013 to 1.4136Median Difference of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Median difference (final values): 0.8836 · 90% CI 0.8351 to 0.9350Median Difference of plasma 3TC has been presented
SecondaryCL/F of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters per hour
CL/F of DTG and 3TC in the Fed State: Part 1
Liters per hourB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG0.8020 ± 32.340.6947 ± 19.99
3TC22.3285 ± 21.0223.3159 ± 18.50
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 0.8661 · 90% CI 0.7658 to 0.9796Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.0442 · 90% CI 0.9951 to 1.0957Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryCL/F of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters per hour
CL/F of DTG and 3TC in the Fed State: Part 2
Liters per hourC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG0.8672 ± 35.930.6542 ± 22.36
3TC20.4890 ± 18.5022.4815 ± 20.34
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 0.7544 · 90% CI 0.6736 to 0.8448Ratio (Cfed/C) of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.0972 · 90% CI 1.0424 to 1.1550Ratio (Cfed/C) of plasma 3TC has been presented
SecondaryTlast of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hours
Tlast of DTG and 3TC in the Fed State: Part 1
HoursB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG71.8265 (71.124 to 72.301)71.9758 (71.330 to 72.869)
3TC71.8265 (71.124 to 72.301)71.9758 (71.330 to 72.869)
SecondaryTlast of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Median · Hours
Tlast of DTG and 3TC in the Fed State: Part 2
HoursC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG72.0292 (71.446 to 72.269)71.8711 (71.080 to 72.381)
3TC72.0292 (71.446 to 72.269)71.8711 (71.080 to 72.381)
SecondaryVz/F of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters
Vz/F of DTG and 3TC in the Fed State: Part 1
LitersB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG16.7520 ± 28.4514.4964 ± 15.87
3TC593.2054 ± 29.23643.0977 ± 41.08
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 0.8654 · 90% CI 0.7629 to 0.9816Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.0841 · 90% CI 0.9139 to 1.2860Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryVz/F of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters
Vz/F of DTG and 3TC in the Fed State: Part 2
LitersC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG19.0954 ± 36.4514.6215 ± 11.63
3TC535.8125 ± 35.63641.3744 ± 32.10
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 0.7657 · 90% CI 0.6702 to 0.8749Ratio (Cfed/C) of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.1970 · 90% CI 1.0869 to 1.3182Ratio (Cfed/C) of plasma 3TC has been presented
SecondaryC24 of DTG and 3TC in the Fed State: Part 1

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
C24 of DTG and 3TC in the Fed State: Part 1
Micrograms per milliliterB: DTG 50 mg/ 3TC 300 mg Monolayer FDCBfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed
DTG0.9216 ± 36.081.1916 ± 25.03
3TC0.0304 ± 33.070.0366 ± 35.90
Statistical analysis
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.2929 · 90% CI 1.1281 to 1.4819Ratio (Bfed/B) of plasma DTG has been presented
  • B: DTG 50 mg/ 3TC 300 mg Monolayer FDC vs Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed · Ratio: 1.2015 · 90% CI 1.1074 to 1.3036Ratio (Bfed/B) of plasma 3TC has been presented
SecondaryC24 of DTG and 3TC in the Fed State: Part 2

Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
C24 of DTG and 3TC in the Fed State: Part 2
Micrograms per milliliterC: DTG 50 mg and 3TC 300 mg Bilayer FDCCfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DTG0.8355 ± 38.461.2273 ± 25.73
3TC0.0350 ± 39.910.0417 ± 38.62
Statistical analysis
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.4690 · 90% CI 1.3009 to 1.6588Ratio (Cfed/C) of plasma DTG has been presented
  • C: DTG 50 mg and 3TC 300 mg Bilayer FDC vs Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed · Ratio: 1.1935 · 90% CI 1.1142 to 1.2785Ratio (Cfed/C) of plasma 3TC has been presented
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Part 1 and 2

SBP and DBP were measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for SBP and DBP for Part 1 and 2 is presented.

Time frame:
Up to Day 31 in Part 1 and Part 2
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Part 1 and 2
Millimeters of mercuryPart 1- A: DTG 50 mg + EPIVIR 300 mgPart 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDCPart 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC FedPart 2- A: DTG 50 mg + EPIVIR 300 mgPart 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDCPart 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
DBP,4 hour,n=75,76,16,75,75,160.1 ± 5.850.2 ± 5.24-2.1 ± 4.19-0.5 ± 4.09-0.3 ± 5.710.0 ± 4.86
DBP,Day 2,n=74,75,16,75,75,16-0.3 ± 5.53-0.9 ± 6.140.4 ± 5.32-1.7 ± 4.87-1.1 ± 4.993.1 ± 5.37
DBP,Day 3,n=74,75,16,75,75,163.2 ± 6.832.7 ± 5.951.3 ± 5.191.7 ± 5.741.2 ± 6.093.4 ± 5.76
DBP,Day 4,n=73,75,16,75,75,167.4 ± 6.475.4 ± 6.646.1 ± 4.224.9 ± 6.515.3 ± 6.118.3 ± 6.94
SBP,4 hour,n=75,76,16,75,75,161.5 ± 6.120.6 ± 5.94-0.8 ± 5.490.0 ± 5.040.5 ± 7.211.0 ± 7.28
SBP,Day 2,n=74,75,16,75,75,16-0.5 ± 6.88-1.4 ± 6.050.4 ± 3.91-1.5 ± 5.10-1.7 ± 7.121.9 ± 8.06
SBP,Day 3,n=74,75,16,75,75,164.0 ± 6.672.7 ± 6.152.9 ± 4.841.9 ± 7.281.6 ± 7.502.3 ± 7.73
SBP,Day 4,n=73,75,16,75,75,168.2 ± 8.097.5 ± 8.437.0 ± 5.807.0 ± 8.867.2 ± 8.727.6 ± 8.42
SecondaryChange From Baseline in Heart Rate (HR): Part 1 and 2

HR was measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for HR for Part 1 and 2 is presented.

Time frame:
Up to Day 31 in Part 1 and Part 2
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate (HR): Part 1 and 2
Beats per minutePart 1- A: DTG 50 mg + EPIVIR 300 mgPart 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDCPart 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC FedPart 2- A: DTG 50 mg + EPIVIR 300 mgPart 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDCPart 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
4 hour,n=75,76,16,75,75,160.6 ± 5.490.4 ± 4.254.9 ± 3.840.1 ± 5.25-0.3 ± 5.433.0 ± 3.22
Day 2,n=74,75,16,75,75,162.2 ± 5.531.9 ± 4.602.9 ± 4.171.6 ± 5.480.6 ± 5.741.6 ± 5.44
Day 3,n=74,75,16,75,75,165.1 ± 8.156.0 ± 6.355.8 ± 6.805.3 ± 7.233.8 ± 7.137.7 ± 10.42
Day 4,n=73,75,16,75,75,167.5 ± 9.288.9 ± 7.689.6 ± 9.158.9 ± 8.316.1 ± 8.399.5 ± 10.10
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 and 2

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia were categorized as SAE. Participants having any AE or SAE are presented.

Time frame:
Up to Week 11
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 and 2
ParticipantsPart 1- A: DTG 50 mg + EPIVIR 300 mgPart 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDCPart 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC FedPart 2- A: DTG 50 mg + EPIVIR 300 mgPart 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDCPart 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
AEs1418115121
SAEs000000

Adverse events

Collected over AEs and SAEs were collected from the start of study treatment until the follow-up contact (Up to 11 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1- A: DTG 50 mg + EPIVIR 300 mg0/75 (0%)0/75 (0%)2/75 (2.7%)
Part 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDC0/76 (0%)0/76 (0%)5/76 (6.6%)
Part 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed0/16 (0%)0/16 (0%)1/16 (6.3%)
Part 2- A: DTG 50 mg + EPIVIR 300 mg0/75 (0%)0/75 (0%)8/75 (10.7%)
Part 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDC0/75 (0%)0/75 (0%)6/75 (8%)
Part 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed0/16 (0%)0/16 (0%)1/16 (6.3%)
Most frequent other events
Most frequent other events
EventPart 1- A: DTG 50 mg + EPIVIR 300 mgPart 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDCPart 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC FedPart 2- A: DTG 50 mg + EPIVIR 300 mgPart 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDCPart 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed
HeadacheNervous system disorders2/755/761/168/756/750/16
ContusionInjury, poisoning and procedural complications0/750/760/160/750/751/16
Skin abrasionInjury, poisoning and procedural complications0/750/760/160/750/751/16

Baseline characteristics

Safety Population: All participants who enrolled in the study and received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Part 1Part 2Total
Mean29.4 ± 9.3731.6 ± 11.1830.5 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female252651
Male5350103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1Part 2Total
American Indian or Alaska Native617
Asian- Central/South Asian Heritage112
Asian- East Asian Heritage011
Asian- South East Asian Heritage101
Black or African American202343
White-White/Caucasian/European Heritage5050100
08

Study locations

1 site
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Aug 2017, 4 months.

Results were first posted in Feb 2019, 1 year 6 months after primary completion.

Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Mar 13, 2017
StartActual
Mar 27, 2017
Primary completionActual
Aug 18, 2017
CompletionActual
Aug 18, 2017
Results first posted
Feb 21, 2019
Last update
Feb 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03078556
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 13, 2017
Start date
Mar 27, 2017
Primary completion
Aug 18, 2017
Completion
Aug 18, 2017
Results posted
Feb 21, 2019
Last update
Feb 21, 2019

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Lamivudine

Start the discussion